Clinical Scorecard: Distribution of Adipose Tissue in Metabolic Disorders: Biology of Specific Depots, Clinical Evaluation, and Therapeutic Interventions
At a Glance
Category
Detail
Condition
Adipose Tissue Distribution in Metabolic Disorders
Key Mechanisms
Differential roles of subcutaneous and visceral adipose tissues in metabolic health.
Target Population
Individuals with obesity and related metabolic disorders.
Care Setting
Clinical evaluation and therapeutic intervention for metabolic health.
Key Highlights
Adipose tissue distribution is a key determinant of metabolic health.
Excess visceral and ectopic fat is linked to insulin resistance and cardiovascular disease.
Lifestyle interventions and specific pharmacological agents can modify adipose distribution.
Imaging and body-composition analysis enhance understanding of fat distribution.
Depot-specific phenotyping is essential for targeted therapeutic strategies.
Guideline-Based Recommendations
Diagnosis
Use waist circumference and waist-to-hip ratio for screening.
Employ imaging techniques for direct characterization of fat distribution.
Management
Implement lifestyle strategies focusing on diet and exercise.
Consider pharmacological options like GLP-1 receptor agonists and TZDs for fat redistribution.
Monitoring & Follow-up
Regular assessment of adipose tissue distribution and metabolic function.
Risks
Increased visceral fat is associated with higher risks of metabolic syndrome and cardiovascular disease.
Patient & Prescribing Data
Patients with obesity and metabolic disorders.
Therapeutic strategies should target metabolically harmful fat distribution rather than total adiposity.
Clinical Best Practices
Adopt an integrated framework linking depot-specific biology with clinical assessment.
Standardize depot-specific phenotyping for precision therapies.
